

Cover Story
By Matthew Bin Han Ong
The NCI-60, a panel of 60 cancer cell lines that have become the Rosetta Stone for the development of anticancer drugs, may be entering its twilight years as NCI develops new, and more expansive, patient-derived xenografts, or PDX models.
In Brief


Funding Opportunities
Drugs & Targets


Trending Stories
- Otis Brawley looks back on a year of great science and greater challenges
- Elisa Rodriguez named first chief diversity and equity officer for faculty at Roswell Park
- Mikaela Naylon Give Kids a Chance Act nixed by Senate
- Gregory Curt, Clinician and Drug Developer, Dies at 64
- Twitter star Vinay Prasad retires @VinayPrasadMD
- Antonio Wolff, Mikala Egeblad named co-directors of Johns Hopkins Kimmel Cancer Center Breast and Gynecologic Cancer Program











